Navigation Links
Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
Date:3/10/2010

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning and Kristalose® (lactulose) for Oral Solution, a prescription laxative. The Company also recently launched Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever available in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed the initial public offering of its common stock in August 2009. For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

About Caldolor'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... -- With all the daily obstacles facing physicians these days, ... patients healthy should be easy. Unfortunately, it isn,t always. ... Act continues to affect the way physicians are reimbursed ... important than ever that medical practices have open and ... for patient care. Each year, cloud-based services ...
(Date:5/27/2015)... Tout voyageur ... Il nuit sérieusement à la productivité. Il ... réunions de mi-journée et vous empêche de ... dans votre chambre d,hôtel. Même une semaine ... de vous empêcher de tenir compagnie à ...
(Date:5/27/2015)... 2015 Research and Markets ... the "2015 Strategies in the European Coagulation ... This comprehensive five-country report contains 500 pages, ... suppliers and potential market entrants identify and evaluate ... market during the next five years. ...
Breaking Medicine Technology:Physicians Seek Payer Inclusion, Not Impediment 2Physicians Seek Payer Inclusion, Not Impediment 3HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 2HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 3HumanCharger, l'allié des sportifs d'élite, vous aide à vaincre le décalage horaire deux fois plus vite 4European Coagulation Testing Market Strategies 2015 2
(Date:5/27/2015)... “ Nursing Homes are starting to supplant ... title of a recent April 2015 New York Times article. ... to the hospital, 20-plus years of research have documented the ... high-quality nursing homes are both safer for older patients and ... nursing homes varying widely, patients and family members may worry ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 While hair ... hair loss, a new pilot study conducted by a ... Surgery (ISHRS) has found hair follicle grafting can help ... research was partially funded by ISHRS, which offers research ... to hair restoration. , In the past decade, ...
(Date:5/27/2015)... The new http://www.carsonenergy.com includes extensive oil ... oil and gas investing, the substantial tax benefits available ... news, IRA investing, definitions and acronyms, info-graphics and educational ... experience is now in one central location, for the ... access 24 hours a day, 7 days a week. ...
(Date:5/27/2015)... NJ (PRWEB) May 27, 2015 ... Network (BCAN) , whose mission is to advance research, ... cancer, have joined forces to battle the fifth most ... in the bladder’s lining start to grow out of ... and their families at every stage of the cancer ...
(Date:5/27/2015)... May 27, 2015 Difass USA, a ... the U.S. with its first three flagship products, Dormiva™, ... purchase nationwide through http://www.difassusa.com . , A ... and productivity, but some people struggle with getting the ... is a sleep aid designed to help you fall ...
Breaking Medicine News(10 mins):Health News:BestNursingHomes.com Launches on National Senior Health and Fitness Day 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2
... 9 Quark Pharmaceuticals, Inc., a development-stage pharmaceutical ... therapeutics, today announced that Bruce A. Molitoris, M.D., ... Indiana University , will present data demonstrating ... disease (AKI and CKD, respectively) of an animal ...
... Prevention Departments are Under-financed, Under-staffed; Patient Safety Weakened , ... are cutting staff, resources and education for infection prevention ... infections is increasing, according to a report released today ... Epidemiology (APIC). , , The "2009 ...
... Rebuild After Physical Activity , , COLUMBUS, Ohio, June 9 ... (NYSE: ABT ) today announced the EAS(R) ... on the go refuel after physical activity. The ready-to-drink sports nutrition ... , , To view the Multimedia News Release, go to: ...
... and dental expand cost-effective solutions for today,s challenging economy ... BlueCross BlueShield (Empire) today announced approval by the New ... Disability insurance as part of their broad benefit portfolio. ... Disability Insurance Company, this addition makes Empire a leading ...
... brain may help you find solutions while asleep, study suggests ... need to solve a problem, sleep on it, researchers suggest. ... University of California, San Diego, researchers say that rapid ... forming new associative networks in the brain. , "We found ...
... June 9 Par Pharmaceutical Companies, Inc. (NYSE: ... spray to the trade. Calcitonin-salmon nasal spray is a ... sales of Miacalcin were approximately $112 million in 2008, according ... Important information about calcitonin-salmon nasal spray , , ...
Cached Medicine News:Health News:Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit 2Health News:Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit 3Health News:Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit 4Health News:Hospital Infection Prevention Resources Cut, Study Says 2Health News:Hospital Infection Prevention Resources Cut, Study Says 3Health News:Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging 2Health News:Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging 3Health News:Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging 4Health News:Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging 5Health News:Empire BlueCross BlueShield Adds Life Insurance, Becomes Full-Service Benefits Provider 2Health News:Empire BlueCross BlueShield Adds Life Insurance, Becomes Full-Service Benefits Provider 3Health News:Empire BlueCross BlueShield Adds Life Insurance, Becomes Full-Service Benefits Provider 4Health News:Got a Problem? Think About It Overnight 2Health News:Par Pharmaceutical Begins Shipment of Generic Miacalcin(R) 2
Comfor™ Cast Boot - Rocker Sole - Closed Toe...
The Multi-Purpose Medical-Surgical Shoe...
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... use as a non-reactive quality assurance reagent in ... gondii (TOXO IgG and TOXO IgM), IgG and ... rubella IgM), IgG and IgM antibodies to cytomegalovirus ... antibodies to herpes simplex virus types 1 and ...
Medicine Products: